Two weeks of pretreatment with escitalopram facilitates extinction learning in healthy individuals

Human Psychopharmacology

Volumn 28, Issue 5, 2013, Pages 447-456

  Bui, Eric ^a,b,c   Orr, Scott P ^a,b   Jacoby, Ryan J ^a   Keshaviah, Aparna ^a   Leblanc, Nicole J ^a   Milad, Mohammed R ^a,b   Pollack, Mark H ^d   Simon, Naomi M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

acute stress disorder; extinction learning; fear acquisition; posttraumatic stress disorder; prevention; SSRI

Indexed keywords

ESCITALOPRAM; PLACEBO;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEAR; FEMALE; HABITUATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORIENTING RESPONSE; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN CONDUCTANCE; TREATMENT DURATION;

ACUTE STRESS DISORDER; EXTINCTION LEARNING; FEAR ACQUISITION; POSTTRAUMATIC STRESS DISORDER; PREVENTION; SSRI;

ADULT; CITALOPRAM; CONDITIONING (PSYCHOLOGY); DOUBLE-BLIND METHOD; EXTINCTION, PSYCHOLOGICAL; FEAR; FEMALE; HUMANS; LEARNING; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84884130008     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2330     Document Type: Article

References (45)

1. Arce E, Simmons A, Lovero K, Stein M, Paulus M,. 2008. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology 196: 661-672.
2. Aronson S, Delgado P,. 2004. Escitalopram. Drugs Today (Barc) 40: 121-131.
3. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J,. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4: 561-571.
4. Beck AT, Epstein N, Brown G, Steer RA,. 1988. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56: 893-897.
5. Bosker FJ, Cremers TI, Jongsma ME, Westerink BH, Wikstrom HV, Den Boer JA,. 2001. Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala. J Neurochem 76: 1645-1653.
6. Bouton ME, Kenney FA, Rosengard C,. 1990. State-Dependent Fear Extinction With Two Benzodiazepine Tranquilizers. Behav Neurosci 104: 44-55.
7. Burghardt NS, Sullivan GM, Mcewen BS, Gorman JM, Ledoux JE,. 2004. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 55: 1171-1178.
8. Costa PT, Mccrae RR,. 1992. Normal personality assessment in clinical practice: The NEO Personality Inventory. Psychol Assess 4: 5-13.
9. Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ,. 2006. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 26: 259-267.
10. Dohrenwend BP, Turner JB, Turse NA, Adams BG, Koenen KC, Marshall R,. 2006. The psychological risks of Vietnam for U.S. veterans: a revisit with new data and methods. Science 313: 979-982.
11. First MB, Spitzer RL, Gibboon M, Williams JBW,. 1994. Structured Clinical Interview for DSM IV Axis I Disorders. New York State Psychiatric Institute: New York, NY.
12. Fowles DC, Christie MJ, Edelberg R, Grings WW, Lykken DT, Venables PH,. 1981. Publication Recommendations for Electrodermal Measurements. Psychophysiology 18: 232-239.
13. Grillon C, Levenson J, Pine DS,. 2007. A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology 32: 225-231.
14. Grillon C, Chavis C, Covington MF, Pine DS,. 2009. Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study. Neuropsychopharmacology 34: 964-971.
15. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM,. 2006. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 59: 816-820.
16. Hofmann SG, Meuret AE, Smits JA, et al,. 2006. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63: 298-304.
17. Hoge EA, Worthington JJ, Nagurney JT, et al,. 2012. Effect of Acute Posttrauma Propranolol on PTSD Outcome and Physiological Responses During Script-Driven Imagery. CNS Neurosci Ther: 18 (1): 21-27.
18. Holbrook TL, Galarneau MR, Dye JL, Quinn K, Dougherty AL,. 2010. Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med 362: 110-117.
19. Ledgerwood L, Richardson R, Cranney J,. 2005. d-cycloserine facilitates extinction of learned fear: Effects on reacquisition and generalized extinction. Biol Psychiatry 57: 841-847.
20. Litz BT, Salters-Pedneault K, Steenkamp MM, et al,. 2012. A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 46: 1184-1190.
21. Mcghee LL, Maani CV, Garza TH, Desocio PA, Gaylord KM, Black IH,. 2009. The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res 30: 92-97.
22. Milad MR, Orr SP, Pitman RK, Rauch SL,. 2005. Context modulation of memory for fear extinction in humans. Psychophysiology 42: 456-464.
23. Milad MR, Goldstein JM, Orr SP, et al,. 2006. Fear conditioning and extinction: influence of sex and menstrual cycle in healthy humans. Behav Neurosci 120: 1196-1203.
24. Milad MR, Orr SP, Lasko NB, Chang Y, Rauch SL, Pitman RK,. 2008. Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. J Psychiatr Res 42: 515-520.
25. Orr SP, Metzger LJ, Lasko NB, Macklin ML, Peri T, Pitman RK,. 2000. De novo conditioning in trauma-exposed individuals with and without posttraumatic stress disorder. J Abnorm Psychol 109: 290-298.
26. Otto MW, Tolin DF, Simon NM, et al,. 2010. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67: 365-370.
27. Peterson RA, Heilbronner RL,. 1987. The Anxiety Sensitivity Index: Construct validity and factor analytic structure. J Anxiety Disord 1: 117-121.
28. Phan KL, Wager T, Taylor SF, Liberzon I,. 2002. Functional Neuroanatomy of Emotion: A Meta-Analysis of Emotion Activation Studies in PET and fMRI. Neuroimage 16: 331-348.
29. Pitman RK, Sanders KM, Zusman RM, et al,. 2002. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 51: 189-192.
30. Pollack MH, Hoge EA, Worthington JJ, et al,. 2011. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 72: 892-897.
31. Rauch SL, Shin LM, Wright CI,. 2003. Neuroimaging Studies of Amygdala Function in Anxiety Disorders. Ann N Y Acad Sci 985: 389-410.
32. Robert R, Blakeney PE, Villarreal C, Rosenberg L, Meyer WJ, 3rd,. 1999. Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study. J Am Acad Child Adolesc Psychiatry 38: 873-882.
33. Roberts NP, Kitchiner NJ, Kenardy J, Bisson JI,. 2010. Early psychological interventions to treat acute traumatic stress symptoms. Cochrane Database Syst Rev 3: CD007944.
34. Schelling G, Kilger E, Roozendaal B, et al,. 2004. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: a randomized study. Biol Psychiatry 55: 627-633.
35. Schilström B, Konradsson-Geuken Å, Ivanov V, et al,. 2011. Effects of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl- d -aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat. Synapse 65: 357-367.
36. Schneier FR, Neria Y, Pavlicova M, et al,. 2012. Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial. Am J Psychiatry 169: 80-88.
37. Shalev AY, Ankri Y, Israeli-Shalev Y, Peleg T, Adessky R, Freedman S,. 2012. Prevention of Posttraumatic Stress Disorder by Early Treatment: Results From the Jerusalem Trauma Outreach and Prevention Study. Arch Gen Psychiatry 69 (2): 166-176.
38. Shin LM, Rauch SL, Pitman RK,. 2006. Amygdala, Medial Prefrontal Cortex, and Hippocampal Function in PTSD. Ann N Y Acad Sci 1071: 67-79.
39. Spielberger CD, Gorsuch RL, Lushene R,. 1970. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto.
40. Stein MB, Kerridge C, Dimsdale JE, Hoyt DB,. 2007. Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 20: 923-932.
41. Taylor FB, Martin P, Thompson C, et al,. 2008. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 63: 629-632.
42. Vaiva G, Ducrocq F, Jezequel K, et al,. 2003. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 54: 947-949.
43. Vrana S, Lauterbach D,. 1994. Prevalence of traumatic events and post-traumatic psychological symptoms in a nonclinical sample of college students. J Trauma Stress 7: 289-302.
44. Wilensky AE, Schafe GE, Kristensen MP, Ledoux JE,. 2006. Rethinking the fear circuit: the central nucleus of the amygdala is required for the acquisition, consolidation, and expression of Pavlovian fear conditioning. J Neurosci 26: 12387- 12396.
45. Windischberger C, Lanzenberger R, Holik A, et al,. 2010. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study. Neuroimage 49: 1161-1170.